Can amlodipine cause gynaecomastia? This is a clinically relevant question for the many men prescribed this widely used calcium channel blocker for hypertension or angina. Gynaecomastia — benign enlargement of male breast glandular tissue — is listed as a very rare adverse reaction in the UK Summary of Product Characteristics (SmPC) for amlodipine, and spontaneous reports have been submitted to the MHRA Yellow Card scheme. Understanding the recognised link, potential mechanisms, risk factors, and when to seek medical advice is important for patients and clinicians managing long-term antihypertensive treatment.

Amlodipine and Gynaecomastia: Is There a Recognised Link?

Gynaecomastia is listed as a very rare adverse reaction to amlodipine in the UK SmPC, and spontaneous reports have been submitted to the MHRA Yellow Card scheme, though causality cannot be confirmed from individual reports.

Experiencing these side effects? Our pharmacists can help you navigate them →

Amlodipine is a widely prescribed calcium channel blocker used to treat hypertension (high blood pressure) and angina. It belongs to the dihydropyridine class of medicines and works by relaxing the smooth muscle in blood vessel walls, reducing the workload on the heart. It is generally well tolerated, with the most commonly reported side effects including peripheral oedema (ankle swelling), flushing, and headache.

Gynaecomastia — the benign enlargement of glandular breast tissue in males — has been reported in association with amlodipine. According to the UK Summary of Product Characteristics (SmPC) for amlodipine, as published on the Electronic Medicines Compendium (EMC), gynaecomastia is classified as a very rare adverse reaction (occurring in fewer than 1 in 10,000 patients), or as frequency not known in some product versions, reflecting the limited data available. This is consistent with the BNF listing for amlodipine.

The Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card scheme has received spontaneous reports of gynaecomastia in patients taking amlodipine. It is important to note that spontaneous reports cannot be used to determine the precise incidence of a side effect or to establish a direct causal relationship; they indicate a signal that warrants awareness.

In case reports, gynaecomastia has generally resolved after dose reduction or discontinuation of amlodipine, though robust evidence on dose-dependence is lacking. If you or someone you care for notices breast tissue enlargement or tenderness whilst taking amlodipine, this should be discussed with a GP or pharmacist promptly — but the medicine should not be stopped without medical advice, as doing so could affect blood pressure control.

How Calcium Channel Blockers May Affect Breast Tissue

No definitive mechanism has been established for amlodipine-induced gynaecomastia; proposed pathways involving hormonal imbalance, CYP3A4 steroid metabolism, or prolactin effects remain speculative and unproven.

The mechanism by which amlodipine might cause gynaecomastia is not established. The available evidence is largely limited to case reports and pharmacovigilance data, and no definitive biological pathway has been confirmed for dihydropyridine calcium channel blockers such as amlodipine.

Several hypothetical mechanisms have been proposed in the medical literature, though these remain speculative and should be interpreted with caution:

• Hormonal imbalance: Gynaecomastia generally arises when the balance between oestrogen and androgen (male sex hormone) activity shifts in favour of oestrogen — through increased oestrogen levels, reduced androgen levels, or increased breast tissue sensitivity to oestrogen. It has been suggested that calcium channel blockers may theoretically influence this balance, though this has not been demonstrated specifically for amlodipine in controlled studies.

• Effects on steroid hormone metabolism: Amlodipine is metabolised primarily via the cytochrome P450 3A4 (CYP3A4) enzyme system in the liver. It has been hypothesised that interactions at this level could alter steroid hormone metabolism, but this remains unproven.

• Prolactin or SHBG effects: Some proposals involve indirect effects on prolactin secretion or sex hormone-binding globulin (SHBG), potentially reducing free testosterone availability. Again, these are theoretical for amlodipine.

It is worth noting that stronger mechanistic evidence for drug-induced gynaecomastia via calcium channel blockade exists for non-dihydropyridine agents such as verapamil, rather than for amlodipine specifically. Patients and clinicians should be aware that the mechanistic basis for amlodipine-associated gynaecomastia remains poorly understood, and the association is based primarily on case reports and post-marketing surveillance (NICE CKS: Gynaecomastia; BMJ Best Practice: Gynaecomastia).

How Common Is This Side Effect and Who Is at Risk?

Gynaecomastia is classified as very rare with amlodipine (fewer than 1 in 10,000); older men, those on multiple medicines, and those with hormonal or metabolic conditions face the greatest risk.

Gynaecomastia associated with amlodipine is classified as a very rare adverse reaction in the UK SmPC (fewer than 1 in 10,000 patients), or as frequency not known in some product versions. In practice, cases may go unreported or be attributed to other causes, making the true incidence difficult to determine. Spontaneous Yellow Card reports cannot be used to calculate incidence.

Certain groups may be at higher risk of developing drug-induced gynaecomastia, based on recognised risk factors for gynaecomastia in general (NICE CKS: Gynaecomastia; BNF):

• Older men: Age-related decline in testosterone levels makes older males more susceptible to gynaecomastia from any cause, including medicines.

• Those on multiple medicines (polypharmacy): Several other drugs can also cause gynaecomastia (see next section), and the cumulative risk in patients on multiple treatments is clinically relevant. This is particularly pertinent in cardiovascular patients, who are often prescribed several agents concurrently.

• Those with underlying hormonal or metabolic conditions: Pre-existing conditions affecting hormone balance — such as hypogonadism, liver disease, chronic kidney disease, or hyperthyroidism — may increase vulnerability.

• Higher doses: Some case reports suggest a possible association with higher doses, but the evidence for dose-dependence is limited and this should not be assumed.

Disentangling the contribution of each medicine to a side effect can be clinically challenging in patients on multiple treatments. A thorough medication review is therefore essential when gynaecomastia is identified.

Other Medicines and Conditions That Can Cause Gynaecomastia

Many medicines — including spironolactone, digoxin, anti-androgens, and some antipsychotics — are more strongly associated with gynaecomastia than amlodipine; underlying conditions such as hypogonadism and liver cirrhosis must also be excluded.

Amlodipine is far from the only medicine associated with gynaecomastia. A broad range of drugs across different therapeutic classes have been implicated, and it is important to consider the full clinical picture before attributing breast tissue changes to any single agent. The following list is aligned with NICE CKS (Gynaecomastia) and the BNF.

Medicines with well-established associations include:

• Spironolactone (a diuretic with anti-androgen properties) — one of the most frequently cited drug causes

• Digoxin — used in heart failure and atrial fibrillation

• Cimetidine and other H2 receptor antagonists

• Anti-androgens used in prostate cancer treatment (e.g., bicalutamide, cyproterone acetate)

• GnRH analogues (e.g., goserelin, leuprorelin) — used in prostate cancer

• Finasteride and dutasteride — used for benign prostatic hyperplasia and hair loss

• Ketoconazole and other azole antifungals

• Oestrogens and anabolic steroids/testosterone therapy — paradoxically, through conversion to oestrogen

• Some antipsychotics and antidepressants — via prolactin elevation

• Some antiretrovirals (e.g., efavirenz)

• Alcohol — through effects on liver metabolism and hormone balance

Medicines with uncertain or debated associations (evidence limited):

• Proton pump inhibitors (e.g., omeprazole) — association is debated; evidence is not conclusive

• Cannabis — some case reports exist, but evidence is uncertain

It is also important to distinguish true gynaecomastia (enlargement of glandular breast tissue) from pseudogynaecomastia (increase in adipose tissue without glandular proliferation), as the two have different causes and management.

Beyond medicines, several medical conditions can independently cause gynaecomastia and must be excluded during assessment:

• Hypogonadism (primary or secondary)

• Hyperthyroidism

• Liver cirrhosis — due to impaired oestrogen metabolism

• Chronic kidney disease

• Testicular or adrenal tumours — rare but important to exclude

Typical evaluation recommended by NICE CKS (Gynaecomastia) includes a thorough history (onset, all current medicines, alcohol and recreational drug use), physical examination (breast tissue, testes, BMI), and targeted investigations. These typically include: liver function tests (LFTs), urea and electrolytes (U&Es), thyroid function tests (TFTs), morning total testosterone, LH and FSH, prolactin, oestradiol, and beta-hCG. Imaging or specialist referral is arranged when malignancy is suspected.

When to Speak to Your GP or Pharmacist

Speak to your GP promptly if you notice breast tissue changes whilst taking amlodipine; urgent referral under NICE NG12 is required for a unilateral lump, nipple discharge, or other features suspicious of malignancy.

If you are taking amlodipine and notice any swelling, tenderness, or enlargement of breast tissue, it is advisable to speak to your GP or pharmacist. Whilst drug-induced gynaecomastia is generally benign and often reversible, it is important to rule out other underlying causes — some of which may require prompt medical attention.

You should contact your GP if you notice:

• Unilateral (one-sided) breast swelling, or a firm, irregular, or hard lump — this requires urgent assessment

• Nipple discharge or nipple retraction

• Rapid or progressive breast enlargement

• Associated symptoms such as unexplained weight loss, fatigue, or changes to the testes (swelling, lump, or pain — which requires urgent urology assessment)

• Breast changes causing significant discomfort or psychological distress

Urgent referral under NICE NG12 (Suspected Cancer: Recognition and Referral): Men aged 30 or over with an unexplained breast lump should be referred urgently via the 2-week-wait pathway to exclude breast malignancy. Men aged 50 or over with unilateral nipple discharge, nipple retraction, or other concerning breast changes should also be referred urgently. If you are concerned about any of these features, do not delay seeking medical advice.

Have questions about your medication? Our pharmacists are here to help →

For most men, bilateral, soft, and mildly tender breast tissue enlargement in the context of a recently started or adjusted medication is likely to be drug-related. However, this should never be assumed without proper clinical evaluation. Your GP may refer you to an endocrinologist or breast clinic depending on the findings.

Do not stop taking amlodipine or any other prescribed medicine without first speaking to a healthcare professional. Abruptly discontinuing antihypertensive treatment can lead to a rebound rise in blood pressure, which carries its own cardiovascular risks. Your GP or pharmacist can help weigh the benefits and risks and explore suitable alternatives if needed.

Reviewing Your Treatment: What the NHS and MHRA Advise

If amlodipine is suspected as the cause, your GP may consider medication review, watchful waiting, dose reduction, or switching to an alternative antihypertensive in line with NICE NG136, without stopping treatment abruptly.

The NHS and MHRA both support a structured approach to managing suspected drug-induced side effects, including gynaecomastia. The MHRA encourages healthcare professionals and patients to report suspected adverse drug reactions through the Yellow Card scheme (available at yellowcard.mhra.gov.uk). Reporting helps build the evidence base for rare or emerging side effects, even where causality cannot be confirmed from individual reports.

If amlodipine is suspected as the cause of gynaecomastia, your GP may consider the following steps in line with good clinical practice and NICE guidance:

• Medication review: Assessing all current medicines for their potential contribution to gynaecomastia, in line with NICE CKS guidance on gynaecomastia

• Watchful waiting: In mild cases, monitoring over several weeks to see whether the condition resolves spontaneously, particularly if no other cause is identified

• Dose reduction: If clinically appropriate, reducing the amlodipine dose may be considered, though evidence that this reliably resolves gynaecomastia is limited and blood pressure control must be maintained

• Switching to an alternative antihypertensive: In line with NICE NG136 (Hypertension in Adults), if a calcium channel blocker is not tolerated, suitable alternatives include a thiazide-like diuretic (e.g., indapamide or chlortalidone), an ACE inhibitor, or an angiotensin receptor blocker (ARB), with the choice guided by the patient's age, ethnicity, and comorbidities. Beta-blockers are not generally recommended as first-line antihypertensive treatment unless there is a specific additional indication (such as angina or certain arrhythmias)

Based on case report evidence, drug-induced gynaecomastia often improves gradually over weeks to months following withdrawal of the causative agent, though the time course varies between individuals. Persistent or severe cases may warrant referral to an endocrinologist or, in rare instances, surgical assessment.

Key UK resources for patients and healthcare professionals:

• MHRA Yellow Card reporting: yellowcard.mhra.gov.uk

• NICE NG136: Hypertension in Adults

• NICE CKS: Gynaecomastia

• NICE NG12: Suspected Cancer — Recognition and Referral

• NHS: Gynaecomastia (nhs.uk)

• BNF: Amlodipine monograph and antihypertensive treatment choices

• MHRA/EMC: Amlodipine Summary of Product Characteristics

Frequently Asked Questions